Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$292,501.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI074252-01A1
Award Id:
88705
Agency Tracking Number:
AI074252
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
138 FARBER HALL, 3435 MAIN STREET, BUFFALO, NY, 14214
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
145056607
Principal Investigator:
() -
Business Contact:
() -
thomasc@therapyx.org
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral strains like avian influenza and the emergence of antibiotic resistant forms of long established pathogens such E. coli underscores the danger from ever evolving pathogens. In this era of expanding infectious threats, the development of novel, effective and practical vaccine adjuvants has lagged considerably. Adjuv ants can be classified as 1) delivery systems or 2) immune potentiators on the basis of their mechanism of action. Immune potentiators, such as cytokines, activate the immune system directly. Delivery system adjuvants serve to concentrate or target vaccine antigens to APCs or to co-localize antigens and immune potentiators. TherapyX, Inc. uses the proprietary phase inversion nanoencapsulation (PIN) technology to create biological adjuvants that combine the properties of an immune potentiator and a delivery system. To this end, TherapyX, Inc. has developed a particulate-based, sustained-release cytokine adjuvant formulation that can induce highly effective TH1 type T-cell and antibody responses. Proof of principle for the efficacy of this formulation has been demonstrated in numerous tumor vaccine studies. More recently, TherapyX, Inc. developed a second generation nanoparticle formulation (TPX-506) that is biologically stable at room temperature for at least one year; making this an ideal adjuvant for vaccina tion against infectious disease in underdeveloped areas of the world. This application will test the efficacy of TPX-506 against extraintestinal pathogenic Escherichia coli (ExPEC) in a mouse urinary tract infection model. The diversity, frequency, potenti al severity, and economic impact of extraintestinal infections due to E. coli are as great as for any bacterial infection. With no other current vaccines available, the successful production this vaccine will address a significant gap in the bacterial prop hylaxis market. PUBLIC HEALTH RELEVANCE - PROJECT NARRATIVE: The diversity, frequency, potential severity, and economic impact of extraintestinal infections due to E. coli are as great as for any bacterial infection. This application will test the efficacy of the TPX-506 vaccine against extraintestinal pathogenic Escherichia coli (ExPEC) infection. With no other current vaccines available, the successful production this vaccine will address a significant gap in the bacterial prophylaxis market.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government